鐢�(ch菐n)鍝佸悕绋� | Bcl2铔嬬櫧淇＞鍥犲瓙鎶楅珨 |
鑻辨枃鍚嶇ū | Anti-Bmf/Bcl2 modifying factor |
瑕�(gu墨)鏍� | 0.2ml/200渭g |
婵冨害 | 1mg/1ml |
鍍�(ji脿)鏍� | 渚�(l谩i)闆诲彲浜彈鍎�(y艒u)鎯� |
鑻辨枃鍚嶇ū Anti-Bmf/Bcl2 modifying factor
涓枃鍚嶇ū Bcl2铔嬬櫧淇＞鍥犲瓙鎶楅珨
婵� 搴� 1mg/1ml
瑕�(gu墨) 鏍� 0.2ml/200渭g
鎶楅珨渚�(l谩i)婧� Rabbit
鍏嬮殕椤炲瀷 polyclonal
浜ゅ弶鍙嶆噳(y墨ng) Human, Mouse, Rat, Dog, Cow, Horse, Rabbit
鐢�(ch菐n)鍝侀鍨� 涓€鎶�
鐮旂┒闋�(l菒ng)鍩� 绱�(x矛)鑳炵敓鐗� 淇¤櫉(h脿o)杞�(zhu菐n)灏�(d菐o) 绱�(x矛)鑳炲噵浜� 绱�(x矛)鑳為鏋�
铔嬬櫧鍒嗗瓙閲� predicted molecular weight: 20kDa
鎬� 鐙€ Lyophilized or Liquid
鍏� 鐤� 鍘� KLH conjugated synthetic peptide derived from humanBcl2 modifying factor (54-88aa)
浜� 鍨� IgG
绱斿寲鏂规硶 affinity purified by Protein A
鍎�(ch菙) 瀛� 娑� Preservative: 15mM Sodium Azide, Constituents: 1%BSA, 0.01M PBS, pH 7.4
鐢�(ch菐n)鍝佹噳(y墨ng)鐢� WB=1:100-500 ELISA=1:500-1000 IP=1:20-100IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
锛堢煶锠熷垏鐗囬渶鍋氭姉鍘熶慨寰�(f霉)锛�
not yet tested in other applications.
optimal dilutions/concentrations should be determined by theend user.
淇濆瓨姊濅欢 Store at -61 掳C for oneyear.
鍒� 鍚� Bcl 2 modifying factor; Bcl-2-modifying factor; Bcl2modifying factor; Bmf; BMF_HUMAN; FLJ00065.
